Young Kim, MD
Gynecologic Oncology · Boston, MANPI 1790875540
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 67.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $502 and has fallen 88.8% since, to $56 in 2023.
Across 10 payments — averaging $65.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$442
- Johnson & Johnson$91
- GSK$44
- KCI USA, Inc.$41
- Agios Pharmaceuticals, Inc.$40
Across 11 payments — averaging $3053.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$25K
- AbbVie$8K
What the payments were for
- Travel & lodging$406%
- Food & beverage$29945%
- Education$31948%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 3 | $442 |
| Johnson & Johnson | 3 | $91 |
| GSK | 2 | $44 |
| KCI USA, Inc. | 1 | $41 |
| Agios Pharmaceuticals, Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$105
How this compares
$658 in reported general payments places this provider in the 55th percentile of 32 gynecologic oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Finasteride | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Boston
- Amy BregarBoston$36K
- Whitfield GrowdonBoston$27K
- Alexander MelamedBoston$5K
- Sarah ParaghamianBoston$3K
- Michael MutoBoston$3K
- Taymaa MayBoston$2K
- Jessica St LaurentBoston$1K
- Leslie GarrettBoston$1K
- Jessica DisilvestroBoston$1K
- Christopher AwtreyBoston$400
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.